This study is looking at how well and how safely a lower weekly dose of doxorubicin works for older patients (ages 65-100) with advanced or metastatic leiomyosarcoma (a type of soft tissue cancer) that cannot be removed by surgery. Doxorubicin is a common chemotherapy drug. Researchers want to see if this weekly schedule can still fight the cancer effectively while being easier to tolerate than standard doses. The main goal is to see how many patients' cancer does not grow or spread for at least 12 weeks. The study is currently recruiting patients.

Study design

This is an open-label, single-arm Phase 2 study aiming to enroll up to 30 patients, with 20 evaluable patients. It uses a Bayesian design with an interim review after 10 patients.

What's involved

After signing consent and screening, you would receive doxorubicin by injection on days 1 and 8 every 21 days for up to 8 cycles. You will also have blood tests and tumor biopsies.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures progression-free survival at 12 weeks, with secondary endpoints including progression-free survival at 6 months and overall survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.